|
aap: CE-approval for new orthopaedic bone cement Hi-Fatigue® G with antibiotics
aap bio implants group, the medical biomaterials division of aap Implantate AG has received CE approval for the new orthopaedic bone cement Hi-Fatigue® G (containing the antibiotic Gentamycin). For the product family Hi-Fatigue® an exclusive distribution agreement was signed with Zimmer. The product will be launched in European markets by Zimmer, the global leader in reconstructive orthopaedic implants within the coming months.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Head of Corporate Communications and Legal Affairs | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
